^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Excerpt:
    ...it is recommended that patients with TP53 deletion/mutation are treated with novel inhibitors (ibrutinib; idelalisib and rituximab) in front-line and relapse settings.
    DOI:
    10.1093/annonc/mdv303
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:…CLL/SLL with del(17p)/TP53 mutation…Other recommended regimens...HDMP + rituximab
    Secondary therapy:
    methylprednisolone acetate
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Clinical study of chemoimmunotherapy with fresh frozen plasma, high dose methylprednisolone and rituximab for ultra-high risk chronic lymphocytic leukemia

    Excerpt:
    ...Ultra-high risk CLL (Meets at least one of the following criteria): (1) ultra high-risk genetics (17p deletion and/or TP53 mutation); (2) short PFS (...
    Trial ID:
    ChiCTR-ONC-12002442
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia

    Excerpt:
    ...Ultra-high risk CLL(Meets at least one of the following criteria) (1)ultra high-risk genetics (17p deletion and/or TP53 mutation) (2)short PFS(...
    Trial ID:
    NCT01670812